Cigna (CI) Stock Still Looks Cheap After a 51% Five Year Run

Cigna Group stock has delivered a solid 51.4% gain over the past five years, yet today it screens as undervalued on broad valuation checks. This raises an obvious question about whether the current price fully reflects the business it represents.

• A 51.4% return over five years suggests Cigna Group has rewarded patient shareholders, while still leaving room for debate on how much future progress is already embedded in the share price.
• The recent launch of Connected Benefits, which ties medical plans with supplemental coverage, can support stronger customer retention and product uptake, while ongoing regulatory scrutiny of the pharmacy benefit management model may pressure pricing and profitability.
• A high value score of 6 out of 6 means the broader market-multiple checks lean cheap rather than expensive for Cigna Group.

The issue now is whether that combination of long term gains and a still cheap overall valuation screen gives Cigna Group meaningful upside from here or mainly reflects the risks on the table.

Spot opportunities like Cigna Group by scanning a hand-picked set of value ideas in the 49 high quality undervalued stocks.

Does Cigna Group Look Undervalued on Earnings?

P/E fits Cigna Group well because earnings still sit at the center of how investors judge large health insurers.

The stock currently trades on a P/E of 11.6x, which is below the broader Healthcare sector average of 25.0x and below the peer group on 31.8x. The model based fair P/E for Cigna Group is 29.7x, which reflects what investors might typically pay for a business with this sector profile, margin structure, scale and risk mix. That gap between 11.6x and 29.7x indicates a wide discount on this earnings measure.

Despite the recent attention around Connected Benefits and pharmacy benefit management scrutiny, the market is still valuing Cigna Group at a P/E multiple that is below both the industry yardstick and the tailored fair ratio.

On earnings, Cigna Group currently looks undervalued based on its P/E multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The Cigna Group Narrative: What Would Justify Today's Price?

Narratives pick up where Cigna Group's valuation puzzle leaves off by spelling out what kind of future on growth, margins and earnings would need to unfold for the current P/E gap to close in either direction. Each scenario ties a rough fair value to a particular path for Cigna Group's catalysts and risks, so you can track which storyline is gaining traction as new information emerges on the Community page.

One of the top community narratives on Cigna Group: 17% undervalued

"Cigna is capitalizing on the growing demand for specialty pharmacy and care services, particularly as chronic diseases and complex treatments become more prevalent..."

Read one of the top narratives on Cigna Group

Do you think there's more to the story for Cigna Group? Head over to our Community to see what others are saying!

The Bottom Line

Cigna Group screens as undervalued on earnings, with the current P/E well below both sector averages and a tailored fair ratio for a business of its profile. That kind of discount only pays off for shareholders if the market eventually gives more credit for its scale, margins and risk mix. The hinge issue is whether concerns around pharmacy benefit management regulation and execution on offerings like Connected Benefits keep a lid on the multiple, or whether the company can show enough resilience that investors are willing to close that gap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com